SOURCE: IO Circuit

July 01, 2013 09:30 ET

Forbes and Motley Fool Discuss Buyouts in Biotech

Note to Editors: The Following Is an Investment Opinion Issued by IO Circuit

NEW YORK, NY--(Marketwired - Jul 1, 2013) - The following is an investment opinion highlighting Theravance (NASDAQ: THRX), VIVUS (NASDAQ: VVUS), Arch Therapeutics (OTCQB: ARTH) and Eli Lilly (NYSE: LLY). In a Motley Fool article titled Which Biotech Company Will Be Bought Next? The case is made for several different potential targets and acquirers in the biotech space, including Eli Lilly (NYSE: LLY) as a possible acquirer of Vivus (NASDAQ: VVUS) and Theravance (NASDAQ: THRX) being a suitable partner for GlaxoSmithKline.

Recently, in a May 27th Forbes article, contributing editor Gene Marcial is quoted saying, "The (biotech) industry is where a big number of investors have doubled or even tripled their money on new drugs that turned out to be blockbusters. So understandably, Wall Street continues to have its eyes glued on the biotechs." (http://www.forbes.com/sites/genemarcial/2013/05/27/tiny-biotech-developing-drugs-akin-to-biogens-rituxan-seen-as-potential-buyout-bet/).

Last week, Arch Therapeutics (OTCQB: ARTH), announced the closing of a reverse acquisition merger and has begun operations as a life science company pursuing the business plan of its newly acquired subsidiary, Arch Biosurgery, Inc. Arch Therapeutics is focused on the development of innovative medical devices designed to stop bleeding and seal tissue. The company's lead product candidate in development, AC5™, is designed to achieve hemostasis in minimally invasive and open surgical procedures

AC5™ is a synthetic peptide comprised of naturally occurring amino acids that when sprayed onto a wound intercalates into the nooks and crannies of the connective tissue where it builds itself into a physical, mechanical structure. AC5™ provides a barrier to leaking substances, including blood and other bodily fluids, regardless of type of surgery or clotting ability. For more information about Arch Therapeutics, AC5™, and its recent merger, please visit www.archtherapeutics.com.

This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Information, opinions and analysis contained herein are based on sources deemed to be reliable and are subject to change without notice. A third party has hired and paid IO Circuit one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Accordingly, certain information included herein may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. No representation, expressed or implied, is made as to the accuracy, completeness or correctness. We accept no liability for any losses arising from an investor's reliance on or use of this report. We do not and have not had any ownership interest in said third party of any kind.

Contact Information